Lee KW, Bai LY, Jung M, Ying J, et al. Phase Ib/II Study of Zanidatamab in Combination with Tislelizumab and Chemotherapy in First-Line HER2-Positive Gastric/Gastroesophageal Junction Adenocarcinoma. Clin Cancer Res 2026;32:312-323.
PMID: 41324998